Evidence map›Paper›PMID 39734349›Full record

ArticleTurkish journal of medical sciences2024

In silico study of bioactive compounds derived from Indonesian marine invertebrates as a novel antituberculosis agent.

Ayu Masyita, Eris Septiana, Asep Bayu, Bustanussalam Bustanussalam, Jonathan A Panggabean, Firdayani Firdayani, Tutik Murniasih

Abstract read
In one paragraph

Article in Turkish journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ayu MasyitaResearch Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Indonesia.ORCID https://orcid.org/0000-0001-9388-8528
Eris SeptianaResearch Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Indonesia.ORCID https://orcid.org/0000-0002-2290-9464
Asep BayuResearch Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Indonesia.ORCID https://orcid.org/0000-0002-5693-0501
Bustanussalam BustanussalamResearch Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Indonesia.ORCID https://orcid.org/0000-0001-5546-8733
Jonathan A PanggabeanPT Biotek Rekayasa Indonesia, Jakarta Timur, Indonesia.ORCID https://orcid.org/0000-0001-7297-0979
Firdayani FirdayaniResearch Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Indonesia.ORCID https://orcid.org/0000-0001-9967-917X
Tutik MurniasihResearch Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, Bogor, Indonesia.ORCID https://orcid.org/0000-0001-7971-2884

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Tuberculosis (TB) has become the world's deadliest disease. The lack of an effective therapeutic drug to treat it is one of the obstacle for doctors. Today, multidrug-resistant TB cases are increasing. Investigating these new drug should be given intensive and careful consideration. Marine invertebrates are valuable since they produce a large number of active compounds, and screening of these active compounds is very important. Materials and methods: Anti-TB screening of compounds derived from marine invertebrates was performed via the in silico method. Three-dimensional structures of pantothenate kinase (MtPanK type 1, PDB ID: 4BFT), Results: The molecular docking analysis showed that the potential candidate compounds with the lowest docking score were 19-hydroxypsammaplysin Q, 19-hydroxypsammaplysin S, psammaplysin L, and psammaplysin K dimethoxy acetal. Several compounds, such as molamide C and the manzamine group, are also potential anti-TB compounds. Conclusion: This study showed that psammaplysin groups have potential as anti-TB compounds. Further laboratory experiments should be done to confirm the in silico data.

Indexed as

Antitubercular AgentsMolecular Docking SimulationMycobacterium tuberculosisAnimalsAquatic OrganismsBacterial ProteinsComputer SimulationHumansIndonesiaInvertebratesOxidoreductasesAntitubercular AgentsBacterial ProteinsInhA protein, MycobacteriumOxidoreductasesantituberculosisMarine natural productsmolecular docking

Identifiers

PMID39734349
PMCPMC11673630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.